Does SELUMETINIB Cause Malignant neoplasm progression? 20 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Malignant neoplasm progression have been filed in association with SELUMETINIB (KOSELUGO). This represents 1.7% of all adverse event reports for SELUMETINIB.
20
Reports of Malignant neoplasm progression with SELUMETINIB
1.7%
of all SELUMETINIB reports
3
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From SELUMETINIB?
Of the 20 reports, 3 (15.0%) resulted in death, 2 (10.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SELUMETINIB. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does SELUMETINIB Cause?
Blood creatine phosphokinase increased (105)
Rash (89)
Off label use (78)
Paronychia (73)
Dermatitis acneiform (61)
Diarrhoea (59)
Fatigue (54)
Acne (52)
Nausea (49)
Death (47)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which SELUMETINIB Alternatives Have Lower Malignant neoplasm progression Risk?
SELUMETINIB vs SEMAGLUTIDE
SELUMETINIB vs SEMUSTINE
SELUMETINIB vs SENNA LEAF
SELUMETINIB vs SENNA LEAF\SENNOSIDES\SENNOSIDES A AND B
SELUMETINIB vs SENNOSIDES